Abstract. Artemisinin-resistant malaria has not been reported from Africa, but resistance can possibly spread from Asia or arise independently in Africa. The emergence of artemisinin resistance in Africa can be monitored by molecular assay of Kelch 13 (K13) propeller sequences. A total of 251 archived DNA samples of Plasmodium falciparum isolates collected in
The emergence of malaria parasites resistant to the majority of conventional antimalarial drugs impedes disease control and compromises malaria elimination programs. For more than a decade, antimalarial chemotherapy has relied on artemisininbased combination therapies (ACTs) to prevent the spread of drug resistance. The rationale for using ACTs lies in the rapid action of artemisinin derivatives to reduce intraerythrocytic parasite load, followed by the elimination of residual parasites by a slower acting drug partner with longer elimination half-life. 1 In Cameroon and Côte d'Ivoire, artesunate-amodiaquine and artemether-lumefantrine are the first-line drugs to treat uncomplicated malaria since 2004. These two ACTs have been shown to be highly effective against acute uncomplicated falciparum malaria in these two countries. 2, 3 Elsewhere in subSaharan Africa, high cure rates, often attaining > 95% after polymerase chain reaction (PCR) correction to exclude reinfections, have been reported with nearly all ACTs. 4 Artemisinin-resistant Plasmodium falciparum was first reported from Cambodia in 2008. 5 Clinical resistance to artemisinin is characterized by delayed parasite clearance, and P. falciparum isolates from patients responding with a long parasite clearance half-life are characterized by high survival rates in vitro using ring-stage survival assay (RSA 0-3h ). 6 Several subsequent studies have shown that resistance to artemisinin has spread throughout southeast Asia. 7, 8 In Africa, artemisinin resistance has not been reported despite the massive use of ACTs.
Several amino acid substitutions in the PF3D7_1343700 gene encoding Kelch propeller domain (K13 propeller) in parasites from western Cambodia have been reported to be associated with delay in parasite clearance after treatment with artemisinin and increased ring-stage survival rate when exposed in vitro to artemisinin. 9 Subsequent studies support the direct association between artemisinin resistance and K13-propeller mutations. 10, 11 Molecular surveillance of K13 propeller may be useful to detect the emergence of artemisininresistant P. falciparum in Africa. 12 The aim of the present study was to analyze the sequence polymorphism in K13-propeller gene of P. falciparum isolates that were collected before and after the effective implementation of the new drug policy based on ACT in Cameroon and Côte d'Ivoire. An aliquot of 1.5 mL of red cell pellet was used for DNA extraction by phenol-chloroform method. A 771-bp fragment of the K13-propeller gene was amplified by PCR as described by Ariey and others. 9 PCR products were sequenced from both the 59 and 39 ends by using an automated DNA sequencer. The procedures for conducting 3 H-hypoxanthinebased in vitro drug sensitivity assay for dihydroartemisinin and the calculation of 50% inhibitory concentration (IC 50 ) were described in our previous study. 14 The deduced K13-propeller amino acid sequences of the isolates were compared with those of Cambodian P. falciparum isolates reported by Ariey and others. 9 The following amino acid substitutions were considered to be key codons: Y493H, R539T, I543T, and C580Y. Moreover, the same study reported that continuous cultivation of F32-Tanzania P. falciparum strain exposed to increasing concentrations of artemisinin resulted in the acquisition of M476I mutant allele in K13.
A The present data demonstrate that all isolates collected in Cameroon and Côte d'Ivoire before the era of ACT were of wild type and that K13-propeller mutants did not emerge among the isolates collected in 2006 (in Cameroon) or in 2013 (in Côte d'Ivoire), soon after the official adoption of ACTs as the first-line drugs. Although a single SNP was observed in one Cameroonian isolate, the role of this amino acid substitution in artemisinin resistance is undetermined. As expected from previous studies, 6 dihydroartemisinin IC 50 was not correlated with K13-propeller sequence variation. In vitro, RSA data would have added more pertinent information on the susceptibility level of these isolates to dihydroartemisinin. The lack of RSA data of our isolates collected between 2002 and 2013 is a major limitation of the present study. Overall, the absence of K13 mutations in Cameroonian and Ivorian isolates collected between 2002 and 2013 is compatible with the more recent findings that there is currently no molecular evidence for artemisinin resistance in Africa. 15 In a recent study, it was also reported that among 11 samples collected in Buea, western Cameroon, in 2013-2014, SNPs were not observed. 16 However, a high level of diversity in K13-propeller sequence was found among 2,000 African isolates across 12 countries, possibly resulting from genetic drift and/or positive selection. 15, 16 Most of the mutations occurred in single parasite populations and were different from those found earlier in Cambodian isolates. In general, the allelic frequencies were < 6% in west and east Africa. Some mutant alleles occurred at a high rate (up to 36%) among parasite populations collected in [2005] [2006] [2007] 
